Treatment Options for Patients With Prostate Cancer
A comprehensive overview of treatment options available for patients with prostate cancer and factors that influence treatment decisions.
EP: 1.Patient Profile 1: A 66-Year-Old-Man with Prostate Cancer
EP: 2.Imaging and Biomarker Testing Considerations in Prostate Cancer
EP: 3.Treatment Options for Patients With Prostate Cancer
EP: 4.High-Risk Prostate Cancer: Treatments Following Radical Prostatectomy
EP: 5.Patient Profile 2: A 78-Year-Old Man with Metastatic Prostate Cancer
EP: 6.Treatment Considerations for Patients With High-Risk, High-Burden Prostate Cancer
EP: 7.Unmet Needs Surrounding the Treatment of Prostate Cancer
Case #1: A 66-Year-Old-Man with Prostate Cancer
Initial Presentation (June 2022)
- A 66-year-old man reported mild urinary frequency to his primary care physician
Clinical workup
- After an elevated serum PSA 22 ng/mL is noted, patient presents to his urologist
- Family history of breast cancer (patient’s mother diagnosed at age 82)
- Digital rectal exam (DRE) unremarkable, overall physical exam unremarkable
- MRI revealed a 40 gm prostate; no extra-prostatic extension, no nodal involvement; 1 ROI, PIRADS-5
- Transperineal (TP) MRI fusion biopsy demonstrated prostate adenocarcinoma andGleason score 8/Grade Group 4 in 9 of 12 tissue samples and Gleason score 9/Grade Group 5 in the region of interest
- Germline genetic testing revealed no actionable mutations; CT and bone scan revealed no extra-prostatic involvement.
Initial Treatment (starting July 2022)
- Patient underwent robotic assisted lap radical prostatectomy (RALP) + PLND; no surgical complications
- Pathology confirmed GG5 prostate disease with pT3bN1R1 designation
- Positive surgical margins; 1 of 12 obturator lymph nodes were positive
12-week Follow-up Notes (October 2022)
- Post-surgical PSA is undetectable at 12 weeks
- Minimal GSI (<1 pad/day)
Study: Lower PCSM is seen with radical prostatectomy vs other modalities
November 14th 2023"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.
Comparing Leuprolide Formulations in Advanced Prostate Cancer
November 13th 2023In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.
